Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines

Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigen-presenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunn, Martin K., Hermans, Ian F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654595/
https://www.ncbi.nlm.nih.gov/pubmed/23734325
http://dx.doi.org/10.4161/onci.23789
_version_ 1782269588371668992
author Hunn, Martin K.
Hermans, Ian F.
author_facet Hunn, Martin K.
Hermans, Ian F.
author_sort Hunn, Martin K.
collection PubMed
description Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigen-presenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has potential for clinical applications.
format Online
Article
Text
id pubmed-3654595
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-36545952013-06-03 Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines Hunn, Martin K. Hermans, Ian F. Oncoimmunology Author's View Invariant natural killer T (iNKT) cells have the capacity to amplify adaptive immune responses by licensing antigen-presenting cells. A simple vaccine consisting of whole tumor cells pulsed with an iNKT-cell agonist efficiently delivers antigens plus adjuvants to endogenous dendritic cells and has potential for clinical applications. Landes Bioscience 2013-04-01 2013-04-01 /pmc/articles/PMC3654595/ /pubmed/23734325 http://dx.doi.org/10.4161/onci.23789 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Hunn, Martin K.
Hermans, Ian F.
Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
title Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
title_full Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
title_fullStr Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
title_full_unstemmed Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
title_short Exploiting invariant NKT cells to promote T-cell responses to cancer vaccines
title_sort exploiting invariant nkt cells to promote t-cell responses to cancer vaccines
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654595/
https://www.ncbi.nlm.nih.gov/pubmed/23734325
http://dx.doi.org/10.4161/onci.23789
work_keys_str_mv AT hunnmartink exploitinginvariantnktcellstopromotetcellresponsestocancervaccines
AT hermansianf exploitinginvariantnktcellstopromotetcellresponsestocancervaccines

Ejemplares similares